Development of aldose reductase inhibitors for the treatment of inflammatory disorders

Bibliography

• Hers HG. Le mécanisme de la transformation de glucose en fructose par les vésicules séminales. Biochim Biophys Acta 1956;22:202‐3
   PubMed Web of Science ®Google Scholar
• Kinoshita JH. A thirty year journey in the polyol pathway. Exp Eye Res 1990;50:567‐73
   PubMed Web of Science ®Google Scholar
• Petrash JM. All in the family: aldose reductase and closely related aldo-keto reductases. Cell Mol Life Sci 2004;61:737‐49
   PubMed Web of Science ®Google Scholar
• Feather MS, Flynn TG, Munro KA, et al. Catalysis of reduction of carbohydrate 2-oxoaldehydes (osones) by mammalian aldose reductase and aldehyde reductase. Biochim Biophys Acta 1995;1244:10‐16
   PubMed Web of Science ®Google Scholar
• Vander Jagt DL, Robinson B, Taylor KK, et al. Reduction of trioses by NADPH-dependent aldo-keto reductases. Aldose reductase, methylglyoxal, and diabetic complications. J Biol Chem 1992;267:4364‐9
   PubMed Web of Science ®Google Scholar
• Ax W, Soldan M, Koch L, et al. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem Pharmacol 2000;59:293‐300
   PubMed Web of Science ®Google Scholar
• Vladykovskaya E, Ozhegov E, Hoetker JD, et al. Reductive metabolism increases the proinflammatory activity of aldehyde phospholipids. J Lipid Res 2011;52:2209‐25
   PubMed Web of Science ®Google Scholar
• Srivastava S, Spite M, Trent JO, et al. Aldose reductase-catalyzed reduction of aldehyde phospholipids. J Biol Chem 2004;279:53395‐406
   PubMed Web of Science ®Google Scholar
• Srivastava S, Watowich SJ, Petrash JM, et al. Structural and kinetic determinants of aldehyde reduction by aldose reductase. Biochemistry 1999;38:42‐54
   PubMed Web of Science ®Google Scholar
• Vander Jagt DL, Kolb NS, Vander Jagt TJ, et al. Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate. Biochim Biophys Acta 1995;1249:117‐26
   PubMed Web of Science ®Google Scholar
• Srivastava S, Chandra A, Bhatnagar A, et al. Lipid peroxidation product, 4-hydroxynonenal and its conjugate with GSH are excellent substrates of bovine lens aldose reductase. Biochem Biophys Res Commun 1995;217:741‐6
   PubMed Web of Science ®Google Scholar
• Hashim Z, Zarina S. Osmotic stress induced oxidative damage: possible mechanism of cataract formation in diabetes. J Diabetes Complications 2012;26:275‐9
   PubMed Web of Science ®Google Scholar
• Alexiou P, Pegklidou K, Chatzopoulou M, et al. Aldose reductase enzyme and its implication to major health problems of the 21(st) century. Curr Med Chem 2009;16:734‐52
   PubMed Web of Science ®Google Scholar
• Keightley JA, Shang L, Kinter M. Proteomic analysis of oxidative stress-resistant cells - a specific role for aldose reductase overexpression in cytoprotection. Mol Cell Proteomics 2004;3:167‐75
   PubMed Web of Science ®Google Scholar
• Spycher SE, Tabataba-Vakili S, O'Donnell VB, et al. Aldose reductase induction: a novel response to oxidative stress of smooth muscle cells. FASEB J 1997;11:181‐8
   PubMed Web of Science ®Google Scholar
• Ramana KV, Srivastava SK. Aldose reductase: a novel therapeutic target for inflammatory pathologies. Int J Biochem Cell Biol 2010;42:17‐20
   PubMed Web of Science ®Google Scholar
• Tammali R, Ramana KV, Singhal SS, et al. Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells. Cancer Res 2006;66:9705‐13
   PubMed Web of Science ®Google Scholar
• Ramana KV, Fadl AA, Tammali R, et al. Aldose reductase mediates the lipopolysaccharide-induced release of inflammatory mediators in RAW264.7 murine macrophages. J Biol Chem 2006;281:33019‐29
   PubMed Web of Science ®Google Scholar
• Chatzopoulou M, Alexiou P, Kotsampasakou E, et al. Novel aldose reductase inhibitors: a patent survey (2006 - present). Expert Opin Ther Pat 2012;22:1303‐23
   PubMed Web of Science ®Google Scholar
• Del Corso A, Cappiello M, Mura U. From a dull enzyme to something else: facts and perspectives regarding aldose reductase. Curr Med Chem 2008;15:1452‐61
   PubMed Web of Science ®Google Scholar
• Steuber H, Czodrowski P, Sotriffer CA, et al. Tracing changes in protonation: a prerequisite to factorize thermodynamic data of inhibitor binding to aldose reductase. J Mol Biol 2007;373:1305‐20
   PubMed Web of Science ®Google Scholar
• Steuber H, Heine A, Podjarny A, et al. Merging the binding sites of aldose and aldehyde reductase for detection of inhibitor selectivity-determining features. J Mol Biol 2008;379:991‐1016
   PubMed Web of Science ®Google Scholar
• Singh R, White MA, Ramana KV, et al. Structure of a glutathione conjugate bound to the active site of aldose reductase. Proteins 2006;64:101‐10
   PubMed Web of Science ®Google Scholar
• Ramana KV, Dixit BL, Srivastava S, et al. Characterization of the glutathione binding site of aldose reductase. Chem Biol Interact 2001;130-132:537‐48
   PubMed Web of Science ®Google Scholar
• Ramana KV, Dixit BL, Srivastava S, et al. Selective recognition of glutathiolated aldehydes by aldose reductase. Biochemistry 2000;39:12172‐80
   PubMed Web of Science ®Google Scholar
• Zentgraf M, Steuber H, Koch C, et al. How reliable are current docking approaches for structure-based drug design? lessons from aldose reductase. Angew Chem Int Ed Engl 2007;46:3575‐8
   PubMed Web of Science ®Google Scholar
• Pietropaolo M, Barinas-Mitchell E, Kuller LH. The heterogeneity of diabetes: unraveling a dispute: is systemic inflammation related to islet autoimmunity? Diabetes 2007;56:1189‐97
   PubMed Web of Science ®Google Scholar
• Cnop M, Welsh N, Jonas JC, et al. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 2005;54(Suppl 2):S97‐107
   PubMedGoogle Scholar
• Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 2009;5:219‐26
   PubMed Web of Science ®Google Scholar
• Snell-Bergeon JK, West NA, Mayer-Davis EJ, et al. Inflammatory markers are increased in youth with type 1 diabetes: the SEARCH Case-Control study. J Clin Endocrinol Metab 2010;95:2868‐76
   Google Scholar
• Jain SK, Kannan K, Lim G, et al. Elevated blood interleukin-6 levels in hyperketonemic type 1 diabetic patients and secretion by acetoacetate-treated cultured U937 monocytes. Diabetes Care 2003;26:2139‐43
   PubMed Web of Science ®Google Scholar
• Katakami N, Kaneto H, Matsuhisa M, et al. Serum interleukin-18 levels are increased and closely associated with various soluble adhesion molecule levels in type 1 diabetic patients. Diabetes Care 2007;30:159‐61
   PubMed Web of Science ®Google Scholar
• Noda K, Nakao S, Ishida S, et al. Leukocyte adhesion molecules in diabetic retinopathy. J Ophthalmol 2012;2012:279037
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Shikata K, Hirata K, et al. Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. Diabetes 1997;46:2075‐81
   PubMed Web of Science ®Google Scholar
• Kador PF, O'Meara JD, Blessing K, et al. Efficacy of structurally diverse aldose reductase inhibitors on experimental periodontitis in rats. J Periodontol 2011;82:926‐33
   PubMed Web of Science ®Google Scholar
• Donath MY, Schumann DM, Faulenbach M, et al. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 2008;31(Suppl 2):S161‐4
   PubMed Web of Science ®Google Scholar
• Duncan BB, Schmidt MI, Pankow JS, et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003;52:1799‐805
   PubMed Web of Science ®Google Scholar
• Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999;353:1649‐52
   PubMed Web of Science ®Google Scholar
• Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E745‐51
   PubMed Web of Science ®Google Scholar
• Pickup JC, Chusney GD, Thomas SM, et al. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 2000;67:291‐300
   PubMed Web of Science ®Google Scholar
• Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002;106:2067‐72
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Stern DM. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol Metab 2000;11:368‐75
   PubMed Web of Science ®Google Scholar
• Srivastava SK, Yadav UCS, Reddy ABM, et al. Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders. Chem Biol Interact 2011;191:330‐8
   PubMed Web of Science ®Google Scholar
• Yamagishi S. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications. Ther Apher Dial 2009;13:534‐9
   PubMed Web of Science ®Google Scholar
• Cosentino F, Eto M, De Paolis P, et al. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells - Role of protein kinase C and reactive oxygen species. Circulation 2003;107:1017‐23
   PubMed Web of Science ®Google Scholar
• Tang WH, Stitham J, Gleim S, et al. Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. J Clin Invest 2011;121:4462‐76
   PubMed Web of Science ®Google Scholar
• Yerneni KK, Bai W, Khan BV, et al. Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Diabetes 1999;48:855‐64
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409‐15
   PubMed Web of Science ®Google Scholar
• Ramana KV, Friedrich B, Srivastava S, et al. Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes 2004;53:2910‐20
   PubMed Web of Science ®Google Scholar
• Ramana KV, Friedrich B, Bhatnagar A, et al. Aldose reductase mediates cytotoxic signals of hyperglycemia and TNF-alpha in human lens epithelial cells. FASEB J 2003;17:315‐17
   PubMed Web of Science ®Google Scholar
• Srivastava SK, Ramana KV, Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev 2005;26:380‐92
   PubMed Web of Science ®Google Scholar
• Fernyhough P, Brewster WJ, Fernandes K, et al. Stimulation of nerve growth factor and substance P expression in the iris-trigeminal axis of diabetic rats-involvement of oxidative stress and effects of aldose reductase inhibition. Brain Res 1998;802:247‐53
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Manna P, Gachhui R, et al. D-Saccharic acid 1,4-lactone protects diabetic rat kidney by ameliorating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via NF-kappaB and PKC signaling. Toxicol Appl Pharmacol 2013;267:16‐29
   PubMed Web of Science ®Google Scholar
• Rashid K, Bhattacharya S, Sil PC. Protective role of D-saccharic acid-1,4-lactone in alloxan induced oxidative stress in the spleen tissue of diabetic rats is mediated by suppressing mitochondria dependent apoptotic pathway. Free Radic Res 2012;46:240‐52
   PubMed Web of Science ®Google Scholar
• Leonard SS, Xia C, Jiang BH, et al. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun 2003;309:1017‐26
   PubMed Web of Science ®Google Scholar
• Bertelli AA, Ferrara F, Diana G, et al. Resveratrol, a natural stilbene in grapes and wine, enhances intraphagocytosis in human promonocytes: a co-factor in antiinflammatory and anticancer chemopreventive activity. Int J Tissue React 1999;21:93‐104
   PubMedGoogle Scholar
• Matsuda H, Morikawa T, Toguchida I, et al. Structural requirements of flavonoids and related compounds for aldose reductase inhibitory activity. Chem Pharm Bull 2002;50:788‐95
   PubMed Web of Science ®Google Scholar
• Palsamy P, Subramanian S. Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochim Biophys Acta 2011;1812:719‐31
   PubMed Web of Science ®Google Scholar
• Shi X, Liao S, Mi H, et al. Hesperidin prevents retinal and plasma abnormalities in streptozotocin-induced diabetic rats. Molecules 2012;17:12868‐81
   PubMed Web of Science ®Google Scholar
• Mahmoud AM, Ashour MB, Abdel-Moneim A, et al. Hesperidin and naringin attenuate hyperglycemia-mediated oxidative stress and proinflammatory cytokine production in high fat fed/streptozotocin-induced type 2 diabetic rats. J Diabetes Complications 2012;26:483‐90
   PubMed Web of Science ®Google Scholar
• Tang J, Du Y, Petrash JM, et al. Deletion of aldose reductase from mice inhibits diabetes-induced retinal capillary degeneration and superoxide generation. Plos One 2013;8:e62081
   PubMed Web of Science ®Google Scholar
• Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 2012;18:3831‐52
   PubMed Web of Science ®Google Scholar
• Marnett LJ. Inflammation and cancer: chemical approaches to mechanisms, imaging, and treatment. J Org Chem 2012;77:5224‐38
   PubMed Web of Science ®Google Scholar
• Tammali R, Srivastava SK, Ramana KV. Targeting aldose reductase for the treatment of cancer. Curr Cancer Drug Tar 2011;11:560‐71
   PubMed Web of Science ®Google Scholar
• Saraswat M, Mrudula T, Kumar PU, et al. Overexpression of aldose reductase in human cancer tissues. Med Sci Monit 2006;12:CR525‐9
   PubMed Web of Science ®Google Scholar
• Tammali R, Ramana KV, Srivastava SK. Aldose reductase regulates TNF-alpha-induced PGE2 production in human colon cancer cells. Cancer Lett (Amsterdam, Neth) 2007;252:299‐306
   PubMed Web of Science ®Google Scholar
• Tammali R, Reddy ABM, Ramana KV, et al. Aldose reductase deficiency in mice prevents azoxymethane-induced colonic preneoplastic aberrant crypt foci formation. Carcinogenesis 2009;30:799‐807
   PubMed Web of Science ®Google Scholar
• Takahashi M, Wakabayashi K. Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Sci 2004;95:475‐80
   PubMed Web of Science ®Google Scholar
• Ramana KV, Tammali R, Srivastava SK. Inhibition of aldose reductase prevents growth factor–induced G1-S phase transition through the AKT/phosphoinositide 3-kinase/E2F-1 pathway in human colon cancer cells. Mol Cancer Ther 2010;9:813‐24
   PubMed Web of Science ®Google Scholar
• Saxena A, Tammali R, Ramana KV, et al. Aldose reductase inhibition prevents colon cancer growth by restoring phosphatase and tensin homolog through modulation of miR-21 and FOXO3a. Antioxid Redox Signal 2013;18:1249‐62
   PubMed Web of Science ®Google Scholar
• Tammali R, Saxena A, Srivastava SK, et al. Aldose reductase inhibition prevents hypoxia-induced increase in hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) by regulating 26 S proteasome-mediated protein degradation in human colon cancer cells. J Biol Chem 2011;286:24089‐100
   PubMed Web of Science ®Google Scholar
• Tammali R, Reddy ABM, Srivastava SK, et al. Inhibition of aldose reductase prevents angiogenesis in vitro and in vivo. Angiogenesis 2011;14:209‐21
   PubMed Web of Science ®Google Scholar
• Kawamura I, Yamamoto N, Sakai F, et al. Activation of lipoprotein lipase and inhibition of B16 melanoma-induced cachexia in mice by ponalrestat, an aldose reductase inhibitor. Anticancer Res 1999;19:341‐8
   PubMed Web of Science ®Google Scholar
• Kawamura I, Lacey E, Yamamoto N, et al. Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome induced by colon26 adenocarcinoma in mice. Anticancer Res 1999;19:4105‐11
   PubMed Web of Science ®Google Scholar
• Kawamura I, Lacey E, Inami M, et al. Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome in nude mice bearing human melanomas G361 and SEKI. Anticancer Res 1999;19:4091‐7
   PubMed Web of Science ®Google Scholar
• Miller SI, Ernst RK, Bader MW. LPS, TLR4 and infectious disease diversity. Nat Rev Microbiol 2005;3:36‐46
   PubMed Web of Science ®Google Scholar
• Pålsson-McDermott EM, O'Neill LAJ. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 2004;113:153‐62
   PubMed Web of Science ®Google Scholar
• Ramana KV, Willis MS, White MD, et al. Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition. Circulation 2006;114:1838‐46
   PubMed Web of Science ®Google Scholar
• Ramana KV, Srivastava SK. Mediation of aldose reductase in lipopolysaccharide-induced inflammatory signals in mouse peritoneal macrophages. Cytokine 2006;36:115‐22
   PubMed Web of Science ®Google Scholar
• Pladzyk A, Reddy ABM, Yadav UCS, et al. Inhibition of aldose reductase prevents lipopolysaccharide-induced inflammatory response in human lens epithelial cells. Invest Ophthalmol Vis Sci 2006;47:5395‐403
   PubMed Web of Science ®Google Scholar
• Ramana KV, Reddy ABM, Tammali R, et al. Aldose reductase mediates endotoxin-induced production of nitric oxide and cytotoxicity in murine macrophages. Free Radical Biol Med 2007;42:1290‐302
   PubMed Web of Science ®Google Scholar
• Shoeb M, Yadav UCS, Srivastava SK, et al. Inhibition of aldose reductase prevents endotoxin-induced inflammation by regulating the arachidonic acid pathway in murine macrophages. Free Radical Biol Med 2011;51:1686‐96
   PubMed Web of Science ®Google Scholar
• Dejager L, Pinheiro I, Dejonckheere E, et al. Cecal ligation and puncture: the gold standard model for polymicrobial sepsis? Trends Microbiol 2011;19:198‐208
   PubMed Web of Science ®Google Scholar
• Reddy ABM, Srivastava SK, Ramana KV. Anti-inflammatory effect of aldose reductase inhibition in murine polymicrobial sepsis. Cytokine 2009;48:170‐6
   PubMed Web of Science ®Google Scholar
• Ravindranath TM, Mong PY, Ananthakrishnan R, et al. Novel role for aldose reductase in mediating acute inflammatory responses in the lung. J Immunol 2009;183:8128‐37
   PubMed Web of Science ®Google Scholar
• Takahashi K, Mizukami H, Kamata K, et al. Amelioration of acute kidney injury in lipopolysaccharide-induced systemic inflammatory response syndrome by an aldose reductase inhibitor, Fidarestat. PLoS One 2012;7:e30134
   PubMed Web of Science ®Google Scholar
• Murdoch JR, Lloyd CM. Chronic inflammation and asthma. Mutat Res 2010;690:24‐39
   PubMed Web of Science ®Google Scholar
• Cho YS, Moon H-B. The role of oxidative stress in the pathogenesis of asthma. Allergy Asthma Immunol Res 2010;2:183‐7
   PubMed Web of Science ®Google Scholar
• Ramana KV, Yadav UCS, Calhoun WJ, et al. Current prospective of aldose reductase inhibition in the therapy of allergic airway inflammation in asthma. Curr Mol Med 2011;11:599‐608
   PubMed Web of Science ®Google Scholar
• Yadav UCS, Ramana KV, Aguilera-Aguirre L, et al. Inhibition of aldose reductase prevents experimental allergic airway inflammation in mice. PLoS One 2009;4:e6535
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AM, Teague WG, Holguin F, et al. Airway glutathione homeostasis is altered in children with severe asthma: evidence for oxidant stress. J Allergy Clin Immunol 2009;123:146‐52
   PubMed Web of Science ®Google Scholar
• Yadav UCS, Ramana KV, Srivastava SK. Aldose reductase inhibition suppresses airway inflammation. Chem Biol Interact 2011;191:339‐45
   PubMed Web of Science ®Google Scholar
• Yadav UCS, Aguilera-Aguirre L, Ramana KV, et al. Aldose reductase inhibition prevents metaplasia of airway epithelial cells. PLoS One 2010;5:e14440
   Google Scholar
• Yadav UCS, Naura AS, Aguilera-Aguirre L, et al. Aldose reductase inhibition suppresses the expression of th2 cytokines and airway inflammation in ovalbumin-induced asthma in mice. J Immunol 2009;183:4723‐32
   PubMed Web of Science ®Google Scholar
• Yadav UCS, Aguilera-Aguirre L, Boldogh I, et al. Aldose reductase deficiency in mice protects from ragweed pollen extract (RWE)-induced allergic asthma. Respir Res 2011;12:145
   PubMed Web of Science ®Google Scholar
• Jiang D, Li Q, Kolosov VP, et al. The inhibition of aldose reductase on mucus production induced by interleukin-13 in the human bronchial epithelial cells. Int Immunopharmacol 2012;12:588‐93
   PubMed Web of Science ®Google Scholar
• Yadav UC, Naura AS, Aguilera-Aguirre L, et al. Aldose reductase inhibition prevents allergic airway remodeling through PI3K/AKT/GSK3beta pathway in mice. PLoS One 2013;8:e57442
   PubMed Web of Science ®Google Scholar
• Gerhardinger C, Dagher Z, Sebastiani P, et al. The transforming growth factor-beta pathway is a common target of drugs that prevent experimental diabetic retinopathy. Diabetes 2009;58:1659‐67
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang P, Jiang T, et al. Role of aldose reductase in TGF-beta1-induced fibronectin synthesis in human mesangial cells. Mol Biol Rep 2010;37:2735‐42
   PubMed Web of Science ®Google Scholar
• Duan W, Aguinaldo Datiles AM, Leung BP, et al. An anti-inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model. Int Immunopharmacol 2005;5:495‐502
   PubMed Web of Science ®Google Scholar
• Duan W, Chan JH, Wong CH, et al. Anti-inflammatory effects of mitogen-activated protein kinase kinase inhibitor U0126 in an asthma mouse model. J Immunol 2004;172:7053‐9
   PubMed Web of Science ®Google Scholar
• Henderson WR Jr, Chi EY, Teo JL, et al. A small molecule inhibitor of redox-regulated NF-kappa B and activator protein-1 transcription blocks allergic airway inflammation in a mouse asthma model. J Immunol 2002;169:5294‐9
   PubMed Web of Science ®Google Scholar
• Yadav UCS, Mishra R, Aguilera-Aguirre L, et al. Prevention of allergic rhinitis by aldose reductase inhibition in a murine model. Inflamm Allergy Drug Targets 2013;12:179‐86
   Google Scholar
• Yadav UCS, Shoeb M, Srivastava SK, et al. Aldose reductase deficiency protects from autoimmune- and endotoxin-induced uveitis in mice. Invest Ophthalmol Visual Sci 2011;52:8076‐85
   PubMed Web of Science ®Google Scholar
• Yadav UCS, Srivastava SK, Ramana KV. Understanding the role of aldose reductase in ocular inflammation. Curr Mol Med 2010;10:540‐9
   PubMed Web of Science ®Google Scholar
• Akagi Y, Yajima Y, Kador PF, et al. Localization of aldose reductase in the human eye. Diabetes 1984;33:562‐6
   PubMed Web of Science ®Google Scholar
• Kern TS, Engerman RL. Distribution of aldose reductase in ocular tissues. Exp Eye Res 1981;33:175‐82
   PubMed Web of Science ®Google Scholar
• Yadav UCS, Srivastava SK, Ramana KV. Inhibition of aldose reductase attenuates endotoxin signals in human non-pigmented ciliary epithelial cells. Exp Eye Res 2010;90:555‐63
   PubMed Web of Science ®Google Scholar
• Yadav UCS, Srivastava SK, Ramana KV. Aldose reductase inhibition prevents endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 2007;48:4634‐42
   PubMed Web of Science ®Google Scholar
• Chang K-C, Laffin B, Ponder J, et al. Beta-glucogallin reduces the expression of lipopolysaccharide-induced inflammatory markers by inhibition of aldose reductase in murine macrophages and ocular tissues. Chem Biol Interact 2013;202:283‐7
   PubMed Web of Science ®Google Scholar
• Fu ZJ, Li S-Y, Kociok N, et al. Aldose reductase deficiency reduced vascular changes in neonatal mouse retina in oxygen-induced retinopathy. Invest Ophthalmol Visual Sci 2012;53:5698‐712
   PubMed Web of Science ®Google Scholar
• Yadav UCS, Shoeb M, Srivastava SK, et al. Amelioration of experimental autoimmune uveoretinitis by aldose reductase inhibition in Lewis rats. Invest Ophthalmol Visual Sci 2011;52:8033‐41
   PubMed Web of Science ®Google Scholar
• O'Connor T, Ireland LS, Harrison DJ, et al. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. Biochem J 1999;343(Pt 2):487‐504
   PubMed Web of Science ®Google Scholar
• Brown KE, Broadhurst KA, Mathahs MM, et al. Immunodetection of aldose reductase in normal and diseased human liver. Histol Histopathol 2005;20:429‐36
   PubMed Web of Science ®Google Scholar
• Wang Z-L, Deng C-Y, Zheng H, et al. (Z)2-(5-(r-methoxybenzylidene)-2, 4-dioxothiazolidin-3-yl) acetic acid protects rats from CCL4-induced liver injury. J Gastroenterol Hepatol 2012;27:966‐73
   PubMed Web of Science ®Google Scholar
• Pandey S, Srivastava SK, Ramana KV. A potential therapeutic role for aldose reductase inhibitors in the treatment of endotoxin-related inflammatory diseases. Exp Opin Investigat Drug 2012;21:329‐39
   PubMed Web of Science ®Google Scholar
• Ramana KV. Aldose reductase: new insights for an old enzyme. Biomol Concepts 2011;2:103‐14
   PubMedGoogle Scholar
• Subbanagounder G, Leitinger N, Schwenke DC, et al. Determinants of bioactivity of oxidized phospholipids. Specific oxidized fatty acyl groups at the sn-2 position. Arterioscler Thromb Vasc Biol 2000;20:2248‐54
   PubMed Web of Science ®Google Scholar
• Gargalovic PS, Imura M, Zhang B, et al. Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. Proc Natl Acad Sci USA 2006;103:12741‐6
   PubMed Web of Science ®Google Scholar
• Bresson E, Lacroix-Pepin N, Boucher-Kovalik S, et al. The prostaglandin F synthase activity of the human aldose reductase AKR1B1 brings new lenses to look at pathologic conditions. Front Pharmacol 2012;3:98
   Google Scholar
• Oates PJ. Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets 2008;9:14‐36
   PubMed Web of Science ®Google Scholar
• Available from: http://apps.who.int/trialsearch/default.aspx
   Google Scholar
• Puppala M, Ponder J, Suryanarayana P, et al. The isolation and characterization of beta-glucogallin as a novel aldose reductase inhibitor from Emblica officinalis. Plos One 2012;7:e31399
   PubMed Web of Science ®Google Scholar
• Akashi H, Han H-J, Iizaka M, et al. Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac. Int J Cancer 2000;88:873‐80
   PubMed Web of Science ®Google Scholar
• Zheng X, Zhang L, Zhai J, et al. The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase. FEBS Lett 2012;586:55‐9
   PubMed Web of Science ®Google Scholar
• Obrosova IG, Kador PF. Aldose reductase/polyol inhibitors for diabetic retinopathy. Curr Pharm Biotechnol 2011;12:373‐85
   PubMed Web of Science ®Google Scholar
• Giannoukakis N. Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications. Expert Opin Investig Drug 2008;17:575‐81
   PubMed Web of Science ®Google Scholar
• Lovering F, Bikker J, Humblet C. Escape from flatland: increasing saturation as an approach to improving clinical success. J Med Chem 2009;52:6752‐6
   PubMed Web of Science ®Google Scholar
• Del-Corso A, Balestri F, Di Bugno E, et al. A new approach to control the enigmatic activity of aldose reductase. PLoS One 2013;8:e74076
   PubMed Web of Science ®Google Scholar
• Burczynski ME, Sridhar GR, Palackal NT, et al. The reactive oxygen species–and Michael acceptor-inducible human aldo-keto reductase AKR1C1 reduces the alpha,beta-unsaturated aldehyde 4-hydroxy-2-nonenal to 1,4-dihydroxy-2-nonene. J Biol Chem 2001;276:2890‐7
   PubMed Web of Science ®Google Scholar
• Barski OA, Tipparaju SM, Bhatnagar A. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev 2008;40:553‐624
   PubMed Web of Science ®Google Scholar
• Mylari BL, Armento SJ, Beebe DA, et al. A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners. J Med Chem 2005;48:6326‐39
   PubMed Web of Science ®Google Scholar
• O'Brien MM, Schofield PJ, Edwards MR. Inhibition of human brain aldose reductase and hexonate dehydrogenase by alrestatin and sorbinil. J Neurochem 1982;39:810‐14
   PubMed Web of Science ®Google Scholar
• Mylari BL, Larson ER, Beyer TA, et al. Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners. J Med Chem 1991;34:108‐22
   PubMed Web of Science ®Google Scholar
• Oka M, Matsumoto Y, Sugiyama S, et al. A potent aldose reductase inhibitor, (2S,4S)-6-fluoro-2', 5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide (Fidarestat): its absolute configuration and interactions with the aldose reductase by X-ray crystallography. J Med Chem 2000;43:2479‐83
   PubMed Web of Science ®Google Scholar
• Ward WHJ, Sennitt CM, Ross H, et al. Ponalrestat: a potent and specific inhibitor of aldose reductase. Biochem Pharmacol 1990;39:337‐46
   PubMed Web of Science ®Google Scholar
• Sugimoto A, Matsui S, Taira M, et al. inventors; Torii Yakuhin Kk, Japan; Asahi Breweries Ltd. assignee. Preparation of (2,4-dioxo-5-methylenethiazolidin-3-yl)acetic acid derivatives and 4-thioxo analogs as aldose reductase inhibitors. JP08109174A; 1996
   Google Scholar